Elanco Animal Health Incorporated
NYSE:ELANDrug Manufacturers - Specialty & Generic
-$0.84 today
- Market cap
- $13.35B
- Beta
- 1.70
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.49
Volume 5.78M
Average 6.04M
ELAN Interest Expense
Cost of servicing the company's debt during the period.
Elanco Animal Health IncorporatedNYSE: ELAN
Interest Expense · Q3 FY2026 · quarter ended Sep 2026
Interest expense grows in line with its trailing trend
Q3 FY2026 interest expense of $59M rose 13.5% year over year, ahead of the +12.2% change in trailing-twelve-month interest expense. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -4.9% a year.
Context
- Interest expense amounted to 4.7% of revenue in FY2025, down 3.0 pp from a year earlier.
- Interest expense increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +13.5% holds above the trailing-twelve-month pace of +12.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 220M USD
- Year-over-year change
- -35.1%
- 4-year CAGR
- -4.5%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 220M | -35.1% |
| FY2024 | 2024-12-31 | 339M | +22.4% |
| FY2023 | 2023-12-31 | 277M | +8.2% |
| FY2022 | 2022-12-31 | 256M | -3.0% |
| FY2021 | 2021-12-31 | 264M | — |
Interest Expense vs competitors
How ELAN compares with its peers on the latest reported figures
- ELAN's LTM Sep 2026 interest expense of $266M is the 2nd highest of the 6 companies compared; the peer median is $56.45M.
- Its year-over-year change of +12.2% is the 2nd highest of 6, against a peer median of -1.0%.
- Interest expense amounts to 5.2% of revenue for ELAN, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.26B | -1.0% | +12.2% | 1.9% | |
| LTM Sep 2026 | $266M | +12.2% | -4.9% | 5.2% | |
| LTM Jun 2026 | $244M | +4.3% | +0.8% | 2.6% | |
| LTM Aug 2026 | $56.45M | -18.7% | +1.0% | 6.4% | |
| LTM Mar 2026 | $45.88M | +26.8% | +40.1% | 3.1% | |
| LTM Sep 2026 | $28.44M | -23.4% | -1.4% | 0.6% | |
| Peer median (excluding ELAN) | $56.45M | -1.0% | +1.0% | 2.6% | |
Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.76B | 4.41B | 4.42B | 4.44B | 4.72B |
| Cost of Revenue | 2.69B | 2.44B | 2.48B | 2.53B | 2.67B |
| Gross Profit | 2.08B | 1.97B | 1.94B | 1.91B | 2.05B |
| Gross Margin | 43.6% | 44.7% | 43.9% | 43.0% | 43.5% |
| Research & Development | 369M | 321M | 327M | 344M | 368M |
| Selling, General & Admin | 1.4B | 1.27B | 1.29B | 1.31B | 1.43B |
| Operating Expenses | 1.77B | 1.59B | 1.61B | 1.66B | 1.8B |
| Depreciation & Amortization | 716M | 682M | 694M | 662M | 680M |
| EBITDA | 409M | 866M | (224M) | 1.49B | 676M |
| EBITDA Margin | 8.6% | 19.6% | -5.1% | 33.5% | 14.3% |
| Operating Income | 304M | 384M | 326M | 251M | 252M |
| Operating Margin | 6.4% | 8.7% | 7.4% | 5.7% | 5.3% |
| Interest Income | 0 | 0 | 0 | 0 | 45M |
| Interest Expense | 264M | 256M | 277M | 339M | 220M |
| Other Income / Expenses | (875M) | (456M) | (1.52B) | 237M | (476M) |
| Income Before Tax | (571M) | (72M) | (1.2B) | 488M | (224M) |
| Pre-Tax Margin | -12.0% | -1.6% | -27.1% | 11.0% | -4.8% |
| Income Tax Expense | (88M) | 6M | 36M | 150M | 8M |
| Net Income | (483M) | (78M) | (1.23B) | 338M | (232M) |
| Net Margin | -10.1% | -1.8% | -27.9% | 7.6% | -4.9% |
| EPS (Basic) | (0.97) | (0.15) | (2.50) | 0.68 | (0.47) |
| EPS (Diluted) | (0.97) | (0.15) | (2.50) | 0.68 | (0.47) |
| Weighted Avg Shares | 487.2M | 488.3M | 492.3M | 494M | 496.4M |
| Weighted Avg Shares (Diluted) | 487.2M | 488.3M | 492.3M | 497.3M | 496.4M |
Elanco Animal Health Incorporated
NYSE:ELAN
Intrinsic Alpha fair value
Locked
Current Price
$26.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.